NCT00555971.
Trial name or title | Therapeutic utility of Xolair in patients undergoing aspirin desensitisation |
Methods | Randomised, double‐blind, parallel‐group study |
Participants | Patients with aspirin‐exacerbated respiratory disease 18 years of age or older |
Interventions | Dosage (150 to 375 mg) based on IgE levels; administered subcutaneously every two to four weeks for 16 weeks versus placebo |
Outcomes | FEV1 and changes in serum and urinary markers of eosinophil activation during desensitisation and change in urinary LTE4 during bronchospasm |
Starting date | May 2006 |
Contact information | http://clinicaltrials.gov/ct2/show/NCT00555971 |
Notes |